Cited by 326Coenzyme Q10 studies and effectsParkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Shults, Clifford W., Haas, Richard H., Passov, David, Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410420221

Open this paper in CoChat — free account

Abstract

The activities of complex I and complex II/III in platelet mitochondria are reduced in patients with early, untreated Parkinson's disease. Coenzyme Q 10 is the electron acceptor for complex I and complex II. We found that the level of coenzyme Q 10 was significantly lower in mitochondria from parkinsonian patients than in mitochondria from age‐ and sex‐matched control subjects and that the levels of coenzyme Q 10 and the activities of complex I and complex II/III were significantly correlated.

Integrity signals

Registry

Crossref · 10.1002/ana.410420221

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Biochemical, physiological and medical aspects of ubiquinone function
Ernster, L., & Dallner, G. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00028-3 · Cited by 1,246
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Oxygen radicals and the nervous system
Halliwell, B. B., & Gutteridge, J. M. C. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90010-4 · Cited by 823
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Self-citation
Lovastatin decreases coenzyme Q levels in humans.
Folkers, K., Langsjoen, P. H., Willis, R. A., Richardson, P. C., Xia, L., Ye, C. Q., & Tamagawa, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.8931 · Cited by 426
Platelet mitochondria function in Parkinson's disease
Krige, D., Carroll, M. T., Cooper, J. A. D., MARSDEN, C. D., & Schapira, A. H. V. (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 358
Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes
Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220

Show all 15 references

Research works printed but not linked: 1

Gotz ME, 1996, Platelet coenzyme Q10 in Parkinson's disease, Mov Disord, 11, 127

Sorted by citations

Items 101–200 of 324

Isolation and Functional Expression of Human COQ3, a Gene Encoding a Methyltransferase Required for Ubiquinone Biosynthesis
Jonassen, T., & Clarke, C. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12381 · Cited by 89
Molecular mechanisms of glutamate neurotoxicity in mixed cultures of NT2‐derived neurons and astrocytes: Protective effects of coenzyme Q10
Sandhu, J. K., Pandey, S., Ribecco‐Lutkiewicz, M., Monette, R., Borowy‐Borowski, H., Walker, P. R., & Sikorska, M. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10579 · Cited by 88
The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: A mini-review
Chiu, H., Venkatakrishnan, K., & Wang, C. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.03.008 · Cited by 86
Coenzyme Q10: is there a clinical role and a case for measurement?
Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed Central · Cited by 87
Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration
Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 89
Combined R‐α–lipoic acid and acetyl‐L‐carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease
Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., Wang, X., Li, X., Luo, C. Y., & Liu, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00390.x · Cited by 88
Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria?
Bogaerts, V., Theuns, J., & Broeckhoven, C. V. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 91
Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases
Testai, L., Martelli, A., Flori, L., Cicero, A. F. G., & Colletti, A. (2021) · Nutrients · doi:10.3390/nu13051697 · Cited by 86
Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
Mounsey, R. B., & Teismann, P. (2010) · Parkinson s Disease · doi:10.4061/2011/617472 · Cited by 86
Antioxidant Therapeutics in Parkinson’s Disease: Current Challenges and Opportunities
Duarte-Jurado, A. P., Gopar‐Cuevas, Y., Cárdenas, O. S., Loera‐Arias, M. D. J., Montes‐de‐Oca‐Luna, R., García‐García, A., & Rodríguez‐Rocha, H. (2021) · Antioxidants · doi:10.3390/antiox10030453 · Cited by 83
Molecular Events Underlying Parkinson’s Disease – An Interwoven Tapestry
Lim, K., & Zhang, C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00033 · Cited by 82
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin
Lim, K.-L., Ng, X.-H., Grace, L. G.-Y., & Yao, T.-P. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4105 · Cited by 64
Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease
Henchcliffe, C., Shungu, D. C., Mao, X., Huang, C. C., Nirenberg, M. J., Jenkins, B. G., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.037 · Cited by 79
Self-citation
Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson’s disease
Zhou, Z., & Tan, E. K. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101107 · Cited by 76
Coenzyme Q treatment of neurodegenerative diseases of aging
Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78
Coenzyme Q10 a mitochondrial restorer for various brain disorders
Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 79
Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients
Winkler‐Stuck, K., Wiedemann, F. R., Wallesch, C., & Kunz, W. S. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.02.003 · Cited by 77
Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults
Miles, M. V., Horn, P. S., Morrison, J. A., Tang, P., deGrauw, T. J., & Pesce, A. J. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00137-2 · Cited by 77
Therapeutic role of coenzyme Q10 in Parkinson's disease
Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81
Self-citation
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R. H., & Iosifescu, D. V. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449303 · Cited by 78
Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson’s Disease
Shahrani, M. M. A., Heales, S., Hargreaves, I. P., & Orford, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110100 · Cited by 79
Parkinson Disease and Exercise
Earhart, G. M., & Falvo, M. J. (2013) · Comprehensive physiology · doi:10.1002/cphy.c100047 · Cited by 80
Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease
Clarke, C. E. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00823-3 · Cited by 72
A responsive outcome for Parkinson's disease neuroprotection futility studies
Elm, J. J., Goetz, C. G., Ravina, B. M., Shannon, K. M., Wooten, G. F., Tanner, C. M., Palesch, Y. Y., Huang, P., Guimarães, P., Kamp, C., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20361 · Cited by 71
Milestones in Huntington disease
Shoulson, I., & Young, A. B. (2011) · Movement Disorders · doi:10.1002/mds.23685 · Cited by 73
Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process
Isobe, C., Abe, T., & Terayama, Y. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5333-x · Cited by 71
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70
Disease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 67
Mitochondrial mechanism of neuroprotection by CART
Mao, P., Ardeshiri, A., Jacks, R., Yang, S., Hurn, P. D., & Alkayed, N. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05691.x · Cited by 69
Use of Statins and the Risk of Parkinson???s Disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00004 · Cited by 66
THE DOPAMINERGIC NIGROSTRIATAL SYSTEMAND PARKINSON'S DISEASE
Hodaie, M., Neimat, J. S., & Lozano, A. M. (2007) · Neurosurgery · doi:10.1227/01.neu.0000249209.11967.cb · Cited by 66
Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington’s Disease
del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., & Jiménez‐Jiménez, F. J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9110-2 · Cited by 63
Mitochondrial Membrane Potential in Aging Cells
Sugrue, M. M., & Tatton, W. G. (2001) · Neurosignals · doi:10.1159/000046886 · Cited by 65
Mitochondrial Dysfunction and Neurodegenerative Disorders: Role of Nutritional Supplementation
Mantle, D., & Hargreaves, I. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012603 · Cited by 64
Effects of Metabolic Modifiers Such as Carnitines, Coenzyme Q10, and PUFAs against Different Forms of Neurotoxic Insults: Metabolic Inhibitors, MPTP, and Methamphetamine
Virmani, A., Gaetani, F., & BINIENDA, Z. K. (2005) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2005.tb00024.x · Cited by 65
Neuroprotection in Parkinson models varies with toxin administration protocol
Anderson, D. W., Bradbury, K. A., & Schneider, J. S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05192.x · Cited by 64
Mitochondrial therapies for Parkinson's disease
Thomas, B., & Beal, M. F. (2010) · Movement Disorders · doi:10.1002/mds.22781 · Cited by 62
Self-citation
Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson’s disease
Foti, S. C., Hargreaves, I. P., Carrington, S., Kiely, A. P., Houlden, H., & Holton, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-42902-7 · Cited by 58
A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?
Clarke, C. E. (2004) · Movement Disorders · doi:10.1002/mds.20057 · Cited by 61
Neuroprotective Actions of Coenzyme Q10 in Parkinson's Disease
Sharma, S., Kheradpezhou, M., Shavali, S., Refaey, H. E., Eken, J., Hagen, C., & Ebadi, M. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82027-5 · Cited by 60
Coenzyme Q10 effects in neurological diseases
Rauchová, H. (2021) · Physiological Research · doi:10.33549/physiolres.934712 · Cited by 68
Mechanisms for Alternative Treatments in Parkinson’s Disease: Acupuncture, Tai Chi, and Other Treatments
Ghaffari, B. D., & Kluger, B. M. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0451-y · Cited by 59
Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease
Beal, M. F., & Shults, C. W. (2003) · BioFactors · doi:10.1002/biof.5520180218 · Cited by 60
Self-citation
Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10
SHARMA, S. K., Refaey, H. E., & Ebadi, M. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.11.019 · Cited by 56
Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis
Murata, T., Ohtsuka, C., & Terayama, Y. (2008) · Free Radical Research · doi:10.1080/10715760701877262 · Cited by 56
Therapeutic Effects of Coenzyme Q10 in Neurodegenerative Diseases
Beal, M. F. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)82026-3 · Cited by 55
Self-citation
Parkinson's Disease: Mitochondrial Molecular Pathology, Inflammation, Statins, and Therapeutic Neuroprotective Nutrition
KONES, R. J. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610373932 · Cited by 57
Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration
Niklowitz, P., Onur, S., Fischer, A., Laudes, M., Palussen, M., Menke, T., & Döring, F. (2016) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.15-73 · Cited by 55
Coenzyme Q10 Metabolism: A Review of Unresolved Issues
Mantle, D., López‐Lluch, G., & Hargreaves, I. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032585 · Cited by 59
Oxidative Stress to Dopaminergic Neurons as Models of Parkinson's Disease
GILLE, G., HUNG, S., REICHMANN, H., & RAUSCH, W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.066 · Cited by 53
Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson's disease
Kuter, K. Z., Kratochwil, M., Berghauzen-Maciejewska, K., Głowacka, U., Sugawa, M. D., Ossowska, K., & Dencher, N. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.01.022 · Cited by 52
Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience
Elm, J. J., Kamp, C., Tilley, B. C., Guimarães, P., Fraser, D., Deppen, P., Brocht, A. F. D., Weaver, C. S., Bennett, S., & NINDS NET‐PD Investigators and Coordinators (2007) · Movement Disorders · doi:10.1002/mds.21409 · Cited by 51
Therapies for Parkinson’s diseases: alternatives to current pharmacological interventions
Li, S., Dong, J., Cheng, C., & Le, W. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1603-9 · Cited by 50
Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease
del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-95 · Cited by 50
Serum levels of coenzyme Q10 in patients with Parkinson's disease
Jiménez‐Jiménez, F. J., Molina, J. A., de Bustos, F., García‐Redondo, A., Gómez-Escalonilla, C., Martínez‐Salio, A., Berbel, Á., Camacho, A., Zurdo, M., Barcenilla, B., et al. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050015 · Cited by 50
Bioenergetic medicine
Swerdlow, R. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12394 · Cited by 51
Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity
Hajieva, P., Mocko, J. B., Moosmann, B., & Behl, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06114.x · Cited by 48
Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients
Gorgone, G., Currò, M., Ferlazzo, N., Parisi, G., Parnetti, L., Belcastro, V., Tambasco, N., Rossi, A., Pisani, F., Calabresi, P., et al. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8174-1 · Cited by 48
Free radical biology in neurological manifestations: mechanisms to therapeutics interventions
Tripathi, R. S., Gupta, R. V., Sahu, M., Srivastava, D., Das, A., Ambasta, R. K., & Kumar, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16693-2 · Cited by 54
Early (Uncomplicated) Parkinson's Disease
Oertel, W. H., Berardelli, A., Bloem, B. R., Bonuccelli, U., Burn, D. J., Deuschl, G., Dietrichs, E., Fabbrini, G., Ferreira, J. J., Friedman, A., et al. (2010) · doi:10.1002/9781444328394.ch14 · Cited by 47
Management of the aging risk factor for Parkinson's disease
Phillipson, O. T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.073 · Cited by 47
Coenzyme Q10, Ageing and the Nervous System: An Overview
Mantle, D., Heaton, R. A., & Hargreaves, I. P. (2021) · Antioxidants · doi:10.3390/antiox11010002 · Cited by 47
Biochemical Diagnosis of Coenzyme Q10 Deficiency
Yubero, D., Montero, R., Artuch, R., Land, J. M., Heales, S., & Hargreaves, I. P. (2014) · Molecular Syndromology · doi:10.1159/000362390 · Cited by 45
Mitochondrial dysfunction and Down's syndrome: Is there a role for coenzyme Q10?
Tiano, L., & Busciglio, J. A. (2011) · BioFactors · doi:10.1002/biof.184 · Cited by 45
Experimental developments in movement disorders: update on proposed free radical mechanisms
Przedborski, S., & Jackson-Lewis, V. R. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00009 · Cited by 45
Implications of metal exposure and liver function in Parkinsonian patients resident in the vicinities of ferroalloy plants
Squitti, R., Gorgone, G., Panetta, V., Lucchini, R. G., Bucossi, S., Albini, E., Alessio, L., Alberici, A., Melgari, J.-M., Benussi, L., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0283-0 · Cited by 44
Mitochondrial dysfunction and possible treatments in Parkinson's disease—a review
Shults, C. W. (2004) · Mitochondrion · doi:10.1016/j.mito.2004.07.028 · Cited by 44
Self-citation
Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
Arduíno, D. M., Esteves, A. R., Oliveira, C. R., & Cardoso, S. M. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966687 · Cited by 44
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
Paumier, K. L., Siderowf, A. D., Auinger, P., Oakes, D., Madhavan, L., Espay, A. J., Revilla, F. J., Collier, T. J., & for the Parkinson Study Group Genetics Epidemiology Working Group (2012) · Movement Disorders · doi:10.1002/mds.24978 · Cited by 43
Targeting cellular energy production in neurological disorders
Baker, S. K., & Tarnopolsky, M. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1655 · Cited by 43
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Brembati, V., Faustini, G., Longhena, F., & Bellucci, A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1197853 · Cited by 43
The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study
Mezawa, M., Takemoto, M., Onishi, S., Ishibashi, R., Ishikawa, T., Yamaga, M., Fujimoto, M., Okabe, E., He, P., Kobayashi, K., et al. (2012) · BioFactors · doi:10.1002/biof.1038 · Cited by 43
Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen‐glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore
Li, G., Zou, L., Cao, C., & Yang, E. S. (2005) · BioFactors · doi:10.1002/biof.5520250111 · Cited by 41
Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis
Jiang, X., Wu, K., Ye, X., Xie, T., Zhang, P., Blass, B. E., & Bai, R. (2023) · Medicinal Research Reviews · doi:10.1002/med.21939 · Cited by 40
Efficacy and Safety of Standardized Extract of Trigonella foenum‐graecum L Seeds as an Adjuvant to L‐Dopa in the Management of Patients with Parkinson's Disease
Nathan, J., Panjwani, S., Mohan, V., Joshi, V., & Thakurdesai, P. A. (2013) · Phytotherapy Research · doi:10.1002/ptr.4969 · Cited by 39
Does High-Dose Coenzyme Q 10 Improve Oxidative Damage and Clinical Outcomes in Parkinson's Disease?
Seet, R. C. S., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chow, A. W. L., Chong, W.-L., Ng, M. P.-E., Ong, C. N., & Halliwell, B. B. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5801 · Cited by 39
Coenzyme Q 10 : Clinical Update and Bioavailability
Bank, G., Kagan, D., & Madhavi, D. (2011) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587211399438 · Cited by 38
Medical treatment of Parkinson’s disease
Fahn, S. (1998) · Journal of Neurology · doi:10.1007/pl00007742 · Cited by 38
Effect of Antioxidants on l-Glutamate and N-Methyl-4-Phenylpyridinium Ion Induced-Neurotoxicity in PC12 Cells
MAZZIO, E. A., Huber, J., Darling‐Reed, S., Harris, N., & Soliman, K. F. A. (2001) · NeuroToxicology · doi:10.1016/s0161-813x(01)00017-1 · Cited by 38
Serum levels of coenzyme Q 10 in patients with Alzheimer's disease
de Bustos, F., Molina, J. A., Jiménez-Jiménez, F. J., García‐Redondo, A., Gómez-Escalonilla, C., Porta-Etessam, J., Berbel, Á., Zurdo, M., Barcenilla, B., Parrilla, G., et al. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050019 · Cited by 37
Evidence for Oxidative Pathways in the Pathogenesis of PD: Are Antioxidants Candidate Drugs to Ameliorate Disease Progression?
Leathem, A., Ortíz, T., Dennis, J. M., & Witting, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136923 · Cited by 36
Baicalein Attenuates Brain Iron Accumulation through Protecting Aconitase 1 from Oxidative Stress in Rotenone-Induced Parkinson’s Disease in Rats
Liu, R., Zhang, S., Zhang, W., Zhao, X., & Du, G. (2022) · Antioxidants · doi:10.3390/antiox12010012 · Cited by 36
The Protective Effects of Mogroside V Against Neuronal Damages by Attenuating Mitochondrial Dysfunction via Upregulating Sirtuin3
Luo, H., Peng, C., Xu, X., Peng, Y., Shi, F., Li, Q., Dong, J., & Chen, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02689-z · Cited by 36
Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection
Kincses, Z. T., & Vécsei, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00150.x · Cited by 39
Coenzyme Q10 for Parkinson's disease
Liu, J., Wang, L., Zhan, S.-Y., & Xia, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008150.pub2 · Cited by 36
Retracted
Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis
Murata, T., Ohtsuka, C., & Terayama, Y. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.09.038 · Cited by 35
Defining disease‐modifying therapies for PD—A road map for moving forward
Olanow, C. W., & Kieburtz, K. D. (2010) · Movement Disorders · doi:10.1002/mds.23288 · Cited by 34
Glycyrrhizic acid renders robust neuroprotection in rodent model of vascular dementia by controlling oxidative stress and curtailing cytochrome-c release
Sathyamoorthy, Y. K., Kaliappan, K., Nambi, P., & Radhakrishnan, R. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1580935 · Cited by 33
Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP−induced Parkinson's disease
Haga, H., Matsuo, K., Yabuki, Y., Zhang, C., Han, F., & Fukunaga, K. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104492 · Cited by 33
Current Management of the Cognitive Dysfunction in Parkinson’s Disease: How Far Have We Come?
Vale, S. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-193 · Cited by 33
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)
Schneider, R. B., Omberg, L., Macklin, E. A., Daeschler, M., Bataille, L., Anthwal, S., Myers, T. L., Baloga, E., Duquette, S., Snyder, P., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51236 · Cited by 31
Coenzyme Q10 for Parkinson's disease
Liu, J., Wang, L., Zhan, S.-Y., & Xia, Y. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008150.pub3 · Cited by 32
Retracted
Coenzyme Q10 serum levels in Huntington’s disease
Andrich, J., Carsten Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., & Müller, T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_13 · Cited by 31
Mitochondrial Abnormalities and Oxidative Imbalance in Neurodegenerative Disease
Ogawa, O., Zhu, X., Perry, G. L., & Smith, M. A. (2002) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2002.41.pe16 · Cited by 31
Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An in vivo volume MRI study
Li, G., Jack, C. R., Yang, X., & Yang, E. S. (2008) · BioFactors · doi:10.1002/biof.5520320120 · Cited by 30
Normal platelet mitochondrial complex I activity in Huntington’s Disease
Powers, W. J., Haas, R., Le, T. P., Videen, T. O., Hershey, T. G., McGee‐Minnich, L., & Perlmutter, J. S. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.008 · Cited by 30
Self-citation
Molecular diagnosis of coenzyme Q10 deficiency: an update
Yubero, D., Montero, R., Santos‐Ocaña, C., Salviati, L., Navas, P., & Artuch, R. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1478290 · Cited by 29
Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
Isobe, C., Abe, T., & Terayama, Y. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000256209 · Cited by 29
Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia
Maguire, Á., Hargreaves, A., & Gill, M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1556481 · Cited by 30
The preclinical detection of Parkinson's disease: Ready for prime time?
Stern, M. B. (2004) · Annals of Neurology · doi:10.1002/ana.20180 · Cited by 30

Authors: Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F.
Affiliations: United States Department of Veterans Affairs (US)
University of California San Diego (US)
Massachusetts General Hospital (US)
Corresponding author: Shults, Clifford W.
ORCID: Haas, Richard H.
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-08
Volume: 42
Issue: 2
Pages: 261-264
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410420221
OpenAlex: W2084464741
Cited by: 326
References: 15
Citations by year: 2026: 3 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 12 · 2021: 14 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 11 · 2014: 16 · 2013: 14 · 2012: 11
FWCI: 2.00
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2625 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ns032365-03, 5r01ns029504-03)
U.S. Public Health Service (P01 12992)
National Institute of Neurological Disorders and Stroke (R01 NS32365, R01 NS29504)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: coenzyme Q10, Parkinson's disease, mitochondrial complex I, platelet mitochondria, mitochondrial electron transport chain, mitochondrial dysfunction
MeSH terms: Blood Platelets, Coenzymes, Female, Humans, Male, Mitochondria, Multienzyme Complexes, Oxidoreductases, Parkinson Disease, Reference Values, Succinate Dehydrogenase, Electron Transport Complex III, Ubiquinone, NAD(P)H Dehydrogenase (Quinone), Electron Transport Complex II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks